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Methods: Polymicrobial contamination induced sepsis mouse model and primary endothelial cells incubated
with sepsis serum were used to study SHP-2 in sepsis-induced endothelial inflammation. SHP-2 activity was
assessed by dephosphorylation of pNPP, ROS production was measured by DCF oxidation and protein interac-
tions were assessed by proximity ligation assay. Vascular inflammation was studied in the mouse cremaster
model and in an in vitro flow assay.
Findings: We identified ROS-dependent inactivation of the tyrosine phosphatase SHP-2 to be decisive for endo-
thelial activation in sepsis. Using in vivo and in vitro sepsis models, we observed a significant reduction of endo-
thelial SHP-2 activity, accompanied by enhanced adhesionmolecule expression. The impaired SHP-2 activitywas
restored by ROS inhibitors and an IL-1 receptor antagonist. SHP-2 activity inversely correlatedwith the adhesive
phenotype of endothelial cells exposed to IL-1β as well as sepsis serum via p38 MAPK and NF-κB. In vivo, SHP-2
inhibition accelerated IL-1β-induced leukocyte adhesion, extravasation and vascular permeability. Mechanisti-
cally, SHP-2 directly interacts with the IL-1R1 adaptor protein MyD88 via its tyrosine 257, resulting in reduced
binding of p85/PI3-K to MyD88.







Sepsisrotein-1; BW, body weight; C, control; CREB, cAMP response element-binding protein; CRP, C-reactive protein; CS, Cys459 to
PI, 4′,6-Diamidin-2-phenylindol; DCF, Dichlorofluorescein; EA, Glu76 to Ala76 mutation (constitutively active SHP-2 mutant).;
nt assay; FITC, fluorescein isothiocyanate; hSerum, human serum; Hsp27, heat shock protein 27; HUVEC, human umbilical vein
1; IKK, IκB kinase; IL-18R, Interleukin-18 receptor; IL-1R1, Interleukin-1 receptor 1; IL-1Ra, Interleukin-1 receptor antagonist; IL-
ogen-activated protein kinase; MyD88 Y257F, Tyr257 to Phe257 mutation of MyD88; MyD88, Myeloid differentiation primary
‘kappa-light-chain-enhancer’ of activated B-cells; PCI, peritoneal contamination and infection; PI3K, Phosphoinositid-3-kinase;
utrophils; PtpI IV, Protein tyrosine phosphatase Inhibitor IV (SHP-2 inhibitor); ROS, Reactive oxygen species; S, Sepsis; SH2 do-
main containing phosphatase-2; TIR domain, Toll/interleukin-1 receptor domain; TLR, Toll-like receptor; VAS-2870, NAD(P)H-
le 1; WT, Wildtype.
perimental Medicine, University Hospital, Ludwig-Maximilians-University, Marchioninistr. 27, München 81377, Germany.
e (H. Mannell).
. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
Sepsis is a life-threatening condition, where
caused by elevated cytokine levels plays a
progression. In sepsis, cytokines such as I
thelium, leading to expression of adhesion
vascular leakage. This mediates adhesion o
extravasation, further promoting inflammat
lar inflammatory response needs to be tight
tissue injury. The tyrosine phosphatase SH
factor and cytokine signalling and is known
thelial physiology but its function in inflamm
vation in sepsis has not been investigated.
Added value of this study
Our study identifies SHP-2 as a new keyplay
dothelial activation in sepsis. We observed
of SHP-2 phosphatase activity in cells of s
tured human endothelial cells treated with
tients, which was accompanied by enhanc
expression. SHP-2 activity was restored b
receptor and inhibition of reactive oxygen
cally, we show by overexpression of differe
tants in endothelial cells that SHP-2 activit
with the adhesive phenotype of EC expos
serum from sepsis patients via regulation o
κB. Accordingly, SHP-2 inhibition accelera
kocyte adhesion, extravasation and v
in vivo. The protective effect of SHP-2 on
was due to interaction of SHP-2 with tyros
adaptor protein MyD88, resulting in reduc
subunit of PI3-Kinase to MyD88.
Implications of all the available evidence
Our data suggest that ROS mediated SHP-
key role in endothelial activation in sepsis.
activity may therefore represent a promisin
a hyperinflammatory state of the endotheliu
thelial dysfunction and capillary leakage in
121Y. Heun et al. / EBioMedicine 42 (2019) 120–132Fund: German Research Foundation, LMU Mentoring excellence and FöFoLe Programme, Verein zur Förderung
von Wissenschaft und Forschung, German Ministry of Education and Research.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).vascular dysfunction
major role in disease
L-1 activate the endo-
molecules and micro-
f leukocytes and their
ion. Hence, the vascu-
ly regulated to prevent
P-2 regulates growth
to play a role in endo-
atory endothelial acti-
er in the control of en-
a significant reduction
eptic mice and in cul-
serum from sepsis pa-
ed adhesion molecule
y blockage of the IL-1
species. Mechanisti-
nt SHP-2 activity mu-
y inversely correlates
ed to IL-1β as well as




ine 257 of the IL-1R1
ed binding of the p85
2 inactivation plays a
Restoration of SHP-2
g target in preventing
m, thus limiting endo-
sepsis.1. Introduction
Sepsis is a severe clinical condition caused by a deregulated systemic
host response to infection leading to organ dysfunction and tissue dam-
age [1,2]. As one of the first lines of defense against infection, cellular
components of innate immunity release inflammatory cytokines such
as interleukin (IL)-1β and tumor necrosis factor α [3]. IL-1β induces en-
dothelial activation, which involves reactive oxygen species (ROS) for-
mation and upregulation of adhesion molecules, a decisive step in the
disease progression of sepsis, mediating the recruitment and adhesionof leukocytes to the endothelium [4,5]. Additionally, IL-1β promotes mi-
crovascular leakage, which is important for leukocyte extravasation [6]
and the development of tissue edema during sepsis [7]. Hence, the dys-
regulation of the endothelium in sepsis is a pivotal component in the
complex process of sepsis, involving several different factors leading to
organ failure [7]. To regain control of the endothelial responses to inflam-
matory stress is thus essential to prevent tissue injury. However, no spe-
cific anti-inflammatory therapy for sepsis is yet available [8]. Therefore, a
deeper understanding of the deregulated endothelial response is of great
importance for the development of future therapeutic strategies.
In sepsis, several signalling pathways have been shown to play a role
in endothelial activation and dysfunction leading to activation of tran-
scription factors like NF-κB and AP-1 [1]. IL-1β signals through the
IL-1R1 inducing binding of the adaptor protein MyD88 to the receptor.
This promotes the generation of a signalling complex (Myddosome)
through interaction of the MyD88 death domain [9], which transduces
downstream signals [10,11]. Additionally, MyD88 has been shown to
harbour a SH2-binding motif, through which it can directly interact
with SH2-containing proteins [12].
The Src-homology 2 (SH2) domain containing tyrosine phosphatase
SHP-2 binds to phosphorylated tyrosines within SH2-binding motifs
and regulates signal transduction by dephosphorylation of tyrosine resi-
dues on receptors and regulatory adaptor proteins [13,14]. Although
SHP-2 has been implicated in the control of growth factor and cytokine
signalling [15–20] and is known to play a role in endothelial physiology
[21–26], its function in inflammatory endothelial activation and the de-
velopment of endothelial dysfunction in sepsis has not been investigated.
Aswe observed a significant reduction of SHP-2phosphatase activity
in endothelial cells exposed to serum from sepsis patients in this study,
we further investigatedwhether this may contribute to the detrimental
dysregulation of endothelial processes in sepsis, such as increased adhe-
sion molecule upregulation, leukocyte recruitment, and vascular per-
meability. We show that SHP-2 becomes inactivated by cytokine-
induced ROS formation in endothelial cells in sepsis, thereby releasing
an inhibitory interaction between SHP-2 and MyD88 and accelerating
the endothelial inflammatory response.
2. Materials and methods
2.1. Antibodies and chemicals
Rabbit phospho-Akt (Ser473) (D9E) XP™ (#4060, RRID: AB_
2315049), rabbit phospho-p38 MAPK (Thr180/Tyr182) (D3F9) XP™
(#4511, RRID:AB_2139682), rabbit phospho-Hsp27 (Ser82) (#2401,
RRID:AB_331644), rabbit VCAM-1 (#12367), rabbit MyD88 (#4283,
RRID:AB_10547882), rabbit NF-κB p65 (D14E12) XP™ (#8242), rabbit
myc-tag (#2278, RRID:AB_490778), rabbit HA-tag (C29F4) (# 3724,
RRID:AB_1549585), rabbit β-Actin (13E5) (#4790) as well as mouse
and rabbit IgG isotype (#5415 and#3900, RRID:AB_1550038) antibodies
were fromCell Signaling Technology. Rabbit ICAM-1 (H-108) (#sc-7891,
RRID:AB_647486),mouse IL-1R1 (#sc-393,998, RRID:AB_2737063), goat
MyD88 (N-19) (#sc-8196, RRID:AB_2146863),mouse SHP-2 (B-1) (#sc-
7384, RRID:AB_628252) and PI3-K p85α (B-9) (#sc-1637) were
from Santa Cruz Biotechnology. Mouse GAPDH (#MAB374) as well as
anti-mouse and rabbit horseradish peroxidase-conjugated secondary
antibodies (#401253 and #401353) were from Merck Millipore. Anti-
rabbit Alexa-fluor 546 labelled antibody (A11035) was from Invitrogen.
Mouse monoclonal APC-labelled ICAM-1 (#559771, RRID:AB_398667),
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(#555751, RRID:AB_398613) for flow cytometry were from BD Biosci-
ences. Recombinant human IL-1βwas purchased from PeproTech. SHP-
2 (PtpI IV) inhibitor was from Merck Millipore. IL-1Ra (# 280-RA) was
from R&D. Alexa-Fluor 488 labelled phalloidin was from Molecular
Probes. All other chemicals were from Sigma-Aldrich.
2.2. Human umbilical vein endothelial cell (HUVEC) culture and treatments
Primary HUVECwere isolated and cultivated as previously described
[27] and used up to passage five.
2.3. Lentiviral constructs and transductions
Expression cassettes for wild type (WT) SHP-2 and the catalytically
inactive mutant SHP-2 CS (Cys459 to Ser459) were kindly provided by
the Bennett laboratory [28]. The constitutively active mutant SHP-2 EA
(Glu76 to Ala) was generated as previously described [26] Lentiviral
particles were produced and physical and biological viral titers were
measured and calculated as previously described [29,30]. Overexpres-
sion of SHP-2 WT and mutant constructs in HUVEC was achieved by
lentiviral transduction, as described elsewhere [26]. Cells were left
72 h for gene expression before assaying.
2.4. Plasmids and transfections
Plasmids for HA-tagged MyD88 wild type (WT) and HA-tagged
MyD88 YF mutant (mutation of Tyr257 to Ala) were kindly provided
by Dr. Rhee and Dr. Pothoulakis [12]. HUVEC were transfected with
MyD88 WT and MyD88 Y257F using jetPRIME transfection reagent
(PeqLab) according to manufacturer's protocol. Cells were used for fur-
ther experiments 48 h after transfection.
2.5. Flow cytometry
Detection and quantification of surface adhesionmolecules (ICAM-1
and VCAM-1) was performed as previously described [27] using APC-
labelled anti-ICAM-1 and VCAM-1 antibodies or IgG1 isotype antibody
as control for background staining.
2.6. Immunoblotting and quantification of protein bands
Lysates were prepared and subjected to SDS-PAGE following
western blotting and protein band intensities quantified as previously
described [26,31].
2.7. Isolation of human polymorphonuclear neutrophils (PMN)
Human PMN were freshly isolated from human whole blood of
healthy donors at the day of the experiment as described elsewhere
[32]. PMN were resuspended in Hank's solution (Biochrom) supple-
mented with 0.25% BSA and 0.1% glucose.
2.8. PMN adhesion assay in vitro
HUVEC expressing the different SHP-2 constructs (WT, CS or EA)
were grown to confluence on μ-channel slides IV0.4 (ibiTreat, IBIDI).
Cells were stimulated with 10 ng/ml IL-1β for 4 h. Isolated human
PMN were stained by incubation with 2 μl/ml 0.05% rhodamine 6G
(R6G) for 5 min at 37 °C in the dark. Stained PMN were pelleted
(300 g, 5 min), resuspended in 37 °C warm phosphate buffered saline
(PBS) supplemented with Ca2+ and Mg2+ and brought to a final con-
centration of 1 × 105 PMN/ml. After priming confluent HUVEC by
15 min perfusion with warm PBS (37 °C) supplemented with Ca2+
and Mg2+ at 1 dyn/cm2 using a syringe pump (kdScientific) slides
were flushed with R6G-stained PMN suspensions for 5 min at1 dyn/cm2. PMN adhering to the EC layer were monitored by fluores-
cence microscopy using the Zeiss Axiovert 200 M microscope, and pic-
tures from four independent areas per channel were taken at 10×
magnification.
2.9. Leukocyte-endothelium interaction and transmigration in vivo
Leukocyte-endothelium-interaction in vivo was assessed in post
capillary venules of the cremaster muscle of 16–18 week old male
C57BL/6J WT mice (Charles River Laboratories). In detail, mice were
treated with PtpI IV or sham solution (DMSO) diluted in 150 μl 0.9%
NaCl for 30 min followed by 4 h of IL-1β stimulation (10 ng/ml) by
intrascrotal injection, respectively. Mice were anesthetized (5 mg/kg
midazolam, 0.5 mg/kg medetomidin, 0.05 mg/kg fentanyl) and the
cremaster muscle was prepared for intravital microscopy as originally
described by Baez et al. [33]. The cremaster muscle was superfused
with 35 °C warm buffered saline and intravital microscopy was per-
formed using a Zeiss Axiotech Vario microscope at 20-fold magnifica-
tion. Leukocyte-endothelium-interaction was recorded in three post
capillary venules per mouse. Mean leukocyte rolling velocities as well
asmicrovascular parameters (venular diameter, venular vessel segment
length) were determined using the Fiji software. No statistical differ-
ence in the blood flow velocities in vessels of the two treatment groups
could be detected, as assessed by the beam length of green fluorescent
microspheres injected via the tail vein (1 mm diameter; Polysciences)
under 20 ms exposure time. Extravasated leukocytes were detected
in 4% formalin-fixed cremaster muscles and stained (Hemacolor,
Millipore) immediately after sacrificing the animals.Microscopy images
were taken from 6 representative areas with 10× magnification.
2.10. Permeability assay in vivo
IL-1β-induced vascular permeability ofmicrovessels was assessed in
the cremaster muscle of 20–25 week old male and female C57BL/6 WT
mice (Charles River Laboratories) by detection of extravasation of the
fluorescent dye FITC-dextran, as previously described [27]. 150 μl of
PtpI IV (2 μM) or sham solution were injected into the scrotum
30 min before preparation of the cremaster muscle. After FITC-dextran
injection and obtaining the first picture, 50 μl of 10 ng/ml IL-1β supple-
mented with 2 μM PtpI IV or sham were applied on the cremaster
muscle tissue.
2.11. Induction of polymicrobial sepsis
Animals were held with ad libitum access to water and a standard
nutritionally complete rodent chow diet and on a 12 h (h) dark-light
cycle in a conventional barrier facility. Polymicrobial sepsis was induced
by peritoneal contamination and infection (PCI) following the protocol
established by Gonnert et al. [34] and as previously performed [35].
Briefly, to induce polymicrobial sepsis, 20–25week oldmale and female
C57BL/6JWTmice (originally obtained from Charles River Laboratories)
were intraperitoneally injected with a standardized and microbiologi-
cally validated human faeces solution (2 μl/g body weight (BW), 650
g-positive colony forming units/μl, 3200 g-negative colony forming
units/μl). The resulting systemic inflammatory reaction reflects several
characteristics of a human sepsis. Sham-treated animals were injected
with 0.9% sodium chloride solution (2 μl/g BW). All sepsis-induced ani-
mals received subcutaneous volume substitution (0.9% sodiumchloride,
25 μl/g BW) every 4 h and antibiotic treatment (Meropenem 25 ml/kg
BW) twice daily. At 24 h and 48 h after PCI the sepsis-induced animals
had lost 8.0 ± 0.6% and 13.6 ± 1.0% body weight, had −4.8 ± 0.6 °C
and − 2.6 ± 0.8 °C decreased body temperature and had a disease se-
verity (clinical sepsis score, CSS, according to Gonnert et al. [34]) of
12.6 ± 0.26 and 12.5 ± 0.65 (CSS at 0 h: 4.0 ± 0), respectively (n =
12). For the CSS maximal 16 points can be reached (Grade IV). For the
definition of the illness severity depending on the points, see Table S1.
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HUVEC expressing the SHP-2 constructs were stimulated with
10 ng/ml IL-1β for 30 min or left non treated. Nuclear translocation
was assessed by immunofluorescence staining of p65 in cells cultured
in 8-well μ-slides (ibiTreat, IBIDI), as previously described [36]. Nuclear
translocation of p65 was quantified by number of stained nuclei nor-
malized to the total number of nuclei per field of view. The specific
DNA binding activity of the NF-κB subunit p65 in nuclear extracts of
HUVEC (1 × 106 cells) was measured in triplicates using the Transcrip-
tion Factor Assay Kit (#KA1341) from Abnova following the manufac-
turer's instructions.2.13. Proximity ligation assay
HUVEC were cultivated on cover slips coated with 0.1% gelatine in
PBS, treated with 10 ng/ml IL-1β and fixed with 1% formalin. Cells
were permeabilized with 0.1% Triton-X in PBS and slides were bordered
using a liquid blocker PAP-Pen (Sigma-Aldrich). DuoLink proximity
ligation assay (Sigma-Aldrich)wasperformed according tomanufactur-
er's protocol. In detail, slides were blocked with Duolink® blocking so-
lution for 1 h following incubation with primary antibodies (1:100)
targeting the interacting proteins and AlexaFluor 488 labelled
phalloidin (1:300, Molecular Probes) diluted in Duolink® AB diluent
for 1 h. Slides were washed three times with Duolink® washing buffer
A for 5 min and appropriate Duolink® PLUS and MINUS PLA probes
were incubated for 1 h. Ligation and amplification of antibody-
conjugated DNA-oligos was performed as described by the manufac-
turer. To visualize nuclei, cells were incubated with DAPI for 5 min be-
fore the final washing step. Slides were air dried at room temperature
and mounted with Dako fluorescence mounting medium. Image acqui-
sition was performed using a Zeiss Axiovert 200 M fluorescence micro-
scope at 40-fold magnification. Data are expressed as number of
interaction spots/cell.2.14. RNA isolation and qRT-PCR
RNA isolation and quantitative reverse-transcriptase PCR was per-
formed as described before [37]. The probes (Applied Biosystems)
used in the experiments included human ICAM-1 NM_000201.2
(#Hs00164932_m1), VCAM-1 NM_001078.3 (#Hs00365486_m1), and
GAPDH NM_002046.3 (#4310884E).2.15. SHP-2 phosphatase activity assay
Phosphatase activity in SHP-2 pull downs was measured as previ-
ously described [26]. To inhibit basal phosphatase activity of SHP-2,
the phosphatase inhibitor Na3VO4 (25mM) or the specific SHP-2 inhib-
itor PtpI IV (2 μM) were added to the substrate solution previous to in-
cubationwith precipitated SHP-2. After incubation for 1h at 37 °C in the
dark, supernatants were transferred to multiwell plates, and extinction
was measured at 405nm (SpectraFluor, Tecan).Table 1
Clinical parameters of sepsis patients, whose blood was used in this study.
Parameter sepsis patientsa Mean ± SEM (range)
Sex (female / male) n = 5 / n = 15
Age (years) 66 ± 2 (41–80)
C-reactive protein (mg/dl) 19.9 ± 2.7 (0.9–34.0)
Leukocyte count (*109/l) 17.1 ± 1.7 (8.5–33.6)
a Parameters were considered within the normal range with CRP values
≤0.5 mg/dl and leukocyte counts between 4 and 10*10 [9]/l.2.16. ROS measurement
Intracellular ROS was measured by ROS-dependent oxidation of
H2–2′,7′-Dichlorofluorescein (H2-DCF) to fluorescent DCF as previ-
ously described [37].
2.17. Measurement of IL-1β concentration in serum
Levels of IL-1β in serum of sepsis patients and healthy participants
were assessed using the human IL-1β/IL-1F12 Quantikine® ELISA
(#DLB50) from R&D according to the manufacturer's instructions.
Levels of IL-1β in serum of PCI mice and healthy littermates were de-
tected using the Mouse IL-1β ELISA Kit (#RAB0275) from Sigma-
Aldrich according to the manufacturer's instructions.
2.18. Statistical analysis
All data are presented as means ± SEM. All statistical analyses were
performed using Sigma Plot 10.0. For comparisons between two groups
of normal distributed data, the student's t-test was used. For compari-
sons between two groups of data lacking normal distribution, a Mann-
Whitney rank sum test was performed. For multiple comparisons of
normal distributed data, the one-way analysis of variance (1-way
ANOVA), followed by Student Newman-Keuls post-hoc test was per-
formed. Differences were considered significant at an error probability
level of p b 0.05.
2.19. Study approvals
All animal studies were conducted in accordance with the Ger-
man animal protection law and approved by the district government
of upper Bavaria (Regierung von Oberbayern, approval reference
number AZ55.2–1-54-2532-172-13) as well as government of Thu-
ringia (Thüringer Landesamt für Lebensmittelsicherheit und
Verbraucherschutz, approval reference number AZ. 02–033/15).
The investigation conforms to the Guide for the Care and Use of Labo-
ratory Animals published by the US National Institutes of Health (NIH
Publication No. 85–23, revised 1996). Serum from patients, who
were diagnosed with sepsis at the intensive care unit of the univer-
sity hospital of Munich, was used for this study (for more informa-
tion see Table 1). Control serum was drawn from healthy donors.
Studies involving patient material were approved by the clinical
ethics committee at the University of Munich, and written informed
consent was received from all participants.
3. Results
3.1. SHP-2 phosphatase activity is repressed in sepsis and causes an exces-
sive inflammatory activation of EC
During systemic infection the endothelium is exposed to a com-
plex composition of inflammatory factors contributing to the induc-
tion of adhesion molecules and disease progression [4,38]. To study
if endothelial SHP-2 activity is affected by the inflammatory condi-
tions in sepsis, we first performed experiments in mice suffering
from polymicrobial sepsis induced by peritoneal contamination
and infection (PCI) [34]. Interestingly, we detected significantly re-
duced SHP-2 phosphatase activity in lungs, which are highly
vascularized organs, of septic mice compared to healthy littermates
at all measured time points (6 h, 24 h and 48 h) (Fig. 1A). The down-
regulated SHP-2 activity was accompanied by significantly enhanced
levels of the cytokine Interleukin (IL)-1β in serum of septic mice
(Fig. 1B). Similarly, analysis of lungs from mice suffering from sepsis
revealed significantly increased Vcam1 and Icam1 expression already
6 h after PCI, which was sustained over 48 h, as compared to
healthy littermates (Fig. 1C). Next, we studied SHP-2 in primary EC
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Fig. 1. Impaired SHP-2 activity in sepsis leads to increased expression of endothelial adhesionmolecules. A) SHP-2 activity was impaired in lungs of animals with polymicrobial sepsis (6 h,
24 h and 48 h upon PCI) compared to sham-treated animals (*p b 0.05, 1-way ANOVA, n=5animals/group). B) IL-1β levels in serumofmicewere increased after PCI induction (*p b 0.05,
1-way ANOVA, n=10 animals/group), asmeasured by ELISA. Numbers below dots showmean IL-1β concentration in pg/ml ± SEM at baseline and 48 h after PCI. C) Expression of Icam1
and Vcam1was induced in PCImice (*p b 0.05, 1-way ANOVA, n=4 animals/group), as assessed by qRT-PCR ofwhole lungs. D) Incubation of ECwith serum from sepsis patients reduced
endothelial SHP-2 phosphatase activity (*p b 0.05, student's t-test, n = 7 patients). E) ICAM-1 and VCAM-1 surface expression was increased upon incubation with serum from sepsis
patients (S) compared to serum fromhealthy donors (C) (*p b 0.05, student's t-test, n= serum from 4 to 5 patientsmeasured in duplicates). F) Incubation of inactive SHP-2 CS expressing
ECwith sepsis serum further enhanced expression of ICAM-1 and VCAM-1 compared to SHP-2WT expressing cells, whereas constitutively active SHP-2 EA expressing cells impaired this,
as assessed by flow cytometry (*p b 0.05, 1-way ANOVA, n = serum from 4 to 5 patients measured in duplicates).
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ilar to septic mice, SHP-2 activity was significantly impaired in pri-
mary EC incubated with sepsis serum (Fig. 1D), as well as in blood
cells of sepsis patients compared to blood cells of healthy donors
(Fig. S1A). Additionally, the reduced SHP-2 activity was associated
with strongly induced adhesion molecule expression (ICAM-1 and
VCAM-1) in EC compared to cells treated with control serum
(Fig. 1E and Fig. S1B). To investigate if the observed reduction of
SHP-2 phosphatase activity is directly linked to the increased inflam-
matory endothelial response seen in sepsis, we treated EC trans-
duced with different SHP-2 mutant constructs with serum from
sepsis patients. The increased ICAM-1 and VCAM-1 expression in-
duced by sepsis serum was even more pronounced in EC expressinga dominant negative, and thus inactive, SHP-2 (CS), as compared to
SHP-2 wild-type (WT) expressing cells (Fig. 1F). In contrast, induc-
tion of SHP-2 activity by expression of a constitutively active SHP-2
(EA) prevented the increase of ICAM-1 and VCAM-1 induced by sep-
sis serum in comparison to SHP-2 WT cells (Fig. 1F).
3.2. SHP-2 phosphatase activity is suppressed by ROS production in sepsis
ROS are known to inactivate phosphatases [39] and are strongly
induced in the endothelium in sepsis [40]. Therefore, we next stud-
ied if inflammatory ROS productionmay be the cause of the observed
SHP-2 inactivation in septic conditions. Indeed, treatment of EC with















































































































































































































































Fig. 2. SHP-2 activity in endothelial cells is inhibited viaROS in inflammation and sepsis. A) Treatment of ECwith serum from sepsis patients (hSerum) induced ROS production, as assessed
byDCF assay (*p b 0.05 vs control serum, student's t-test, n=serum from6patients). B) Incubationwith theNAD(P)H-oxidase inhibitor VAS-2870 (5 μM)prior to stimulationwith human
sepsis serumprevented the decrease of SHP-2 activity in EC (*p b 0.05, 1-way ANOVA, n= serum from4 to 7 patients). C) Analysis (ELISA) of serum from sepsis patients showed enhanced
IL-1β concentrations compared to healthy donors (*p b 0.05, student's t-test, n = 7 patients measured in duplicates). D) IL-1β stimulation (10 ng/ml) induced ROS production in EC, as
measured by the DCF assay (***p b 0.001, Mann-Whitney rank sum test, n = 3 in octuplicates). E) Stimulation with IL-1β (10 ng/ml, 4 h) repressed SHP-2 phosphatase activity in EC
(*p b 0.05, 1-way ANOVA, n = 4). As a control, cells were incubated with an IL-1R antagonist (40 ng/ml) prior to incubation with IL-1β. F) Incubation with ROS inhibitors NAC
(10 mM) or VAS-2870 (5 μM) prior to IL-1β stimulation restored the diminished SHP-2 activity in EC (*p b 0.05, 1-way ANOVA, n = 6–7). G) Treatment of EC with an IL-1R antagonist
(40 ng/ml) prior to exposure to serum from sepsis patients restored SHP-2 activity (*p b 0.05, 1-way ANOVA on ranks, n = 12–15).
125Y. Heun et al. / EBioMedicine 42 (2019) 120–132release (Fig. 2A). SHP-2 had a high basal phosphatase activity in EC,
since incubation with the general phosphatase inhibitor sodium
orthovanadate as well as with the pharmacological SHP-2 inhibitor
PtpI IV reduced the phosphatase activity by 60% ± 16% and 68% ±
11% below basal levels, respectively (Fig. S2A), similar to sepsis
serum. Importantly, the decrease in endothelial SHP-2 activity ob-
served after exposure to serum from sepsis patients (in Fig. 1D)
was restored upon selective inhibition of the NAD(P)H-oxidase
(VAS-2870) (Fig. 2B), indicating a ROS-dependent mechanism. To
investigate if cytokines released in sepsis induces ROS formation
and thus are the upstream source of SHP-2 inactivation, we mea-
sured IL-1β levels in serum from sepsis patients. Similar to septic
mice, significantly enhanced IL-1β concentrations were detected inhuman sepsis serum (Fig. 2C) and IL-1β exposure induced ROS pro-
duction in EC (Fig. 2D). Interestingly, IL-1β treatment reduced endo-
thelial SHP-2 activity, similar to sepsis serum (Fig. 2E). Furthermore,
the reduced SHP-2 activity observed upon IL-1β stimulation was
completely rescued when cells were incubated with the general
anti-oxidant N-acetylcysteine (NAC) as well as with the NAD(P)H-
oxidase inhibitor VAS-2870 (Fig. 2F). Of note, treatment of EC with
IL-1 receptor-antagonist (IL-1Ra) prior to exposure to sepsis serum
prevented SHP-2 inactivation (Fig. 2G). As IL-1α also signals through
the IL-1R [10] and is released during sepsis [41], we measured SHP-2
activity upon IL-1α stimulation. In contrast to IL-1β stimulation,
IL-1α failed to inactivate SHP-2 (Fig. S2B), indicating a major contri-
bution of IL-1β in sepsis induced SHP-2 inactivation.
















































































































































































































































































Fig. 3. Inhibition of SHP-2 phosphatase activity augments IL-1β-induced vascular
inflammation in vivo. Leukocyte recruitment was assessed in post capillary venules of
the mouse cremaster muscle after treatment with IL-1β (10 ng/ml) in combination with
the pharmacological SHP-2 inhibitor PtpI IV (2 μM) or sham solution for 4 h by intravital
microscopy. A) Number of rolling leukocytes and leukocyte rolling velocity was reduced
upon SHP-2 inhibition (*p b 0.05, **p b 0.01, student's t-test, n = 4–5 animals/group,
126 Y. Heun et al. / EBioMedicine 42 (2019) 120–1323.3. Loss of SHP-2 activity enhances IL-1β-induced endothelial inflamma-
tion in vivo
To further study the physiological impact of SHP-2 inactivation in an
inflammatory setting and having observed that SHP-2 activity can be re-
stored by IL-1R blockage in sepsis, we investigated the influence of
SHP-2 activity on IL-1β-induced endothelial activation in vivo. Leuko-
cyte recruitment was studied in postcapillary venules of the cremaster
muscle of mice 4 h after treatment with IL-1β. To mimic the in vivo sit-
uation with reduced SHP2 activity in sepsis (Fig. 1A, D), mice were
treatedwith the pharmacological SHP-2 inhibitor PtpI IV, which also en-
hanced IL-1β-induced endothelial ICAM-1 and VCAM-1 expression
(Fig. S3A). The number of rolling leukocytes as well as the mean leuko-
cyte rolling velocity was significantly decreased in animals receiving
PtpI IV compared to sham treated animals (Fig. 3A). As a consequence,
PtpI IV treatment significantly increased leukocyte adhesion (Fig. 3B).
As EC permeability is a further hallmark of inflammation during sepsis
and also determines leukocyte transmigration into the tissue, we
assessed this parameter in the mouse cremaster muscle measuring
FITC-dextran extravasation. Treatment with the SHP-2 inhibitor PtpI
IV further augmented the IL-1β-induced vascular permeability of
microvessels in vivo compared to sham treatment (Fig. 3C). In accor-
dance with that, PtpI IV treatment enhanced leukocyte extravasation
4 h after IL-1β application compared to IL-1β treatment alone (Fig. 3D).
To further verify the functional relevance of SHP-2 inhibition in the
endothelium, we analyzed adhesion molecule expression and func-
tional adhesion of isolated human leukocytes to EC expressing the dif-
ferent SHP-2 mutants (WT, CS and EA) under flow (1 dyn/cm2). This
revealed that the increased number of adherent leukocytes after 4 h of
IL-1β stimulation to SHP-2 WT expressing EC was even more pro-
nounced in dominant negative SHP-2 CS expressing cells due to en-
hanced surface expression of VCAM-1 and ICAM-1 in these cells
(Fig. 3E, F and S3B), similarly to pharmacological SHP-2 inhibition
in vivo. In contrast, expression of constitutively active SHP-2 EA in EC
significantly impaired adhesion molecule expression and accordingly
leukocyte adhesion (Fig. 3E, F and S3B).3.4. SHP-2 controls IL-1β-induced downstream signalling by a regulatory
interaction with MyD88
Next, we sought to identify the specific signalling pathway affected
by SHP-2 phosphatase activity during IL-1β-induced inflammation in
sepsis. Firstly, pharmacological inhibition of the transcription factors
AP-1 (c-jun), CREB and NF-κB showed that only inhibition of NF-κB af-
fects IL-1β-induced ICAM-1 or VCAM-1 expression (Fig. S4A). Overex-
pression of SHP-2 CS in EC enhanced IL-1β-induced NF-κB activation2–3 venules/animal). B) SHP-2 inhibition further enhanced leukocyte adherence to the
vessel wall compared to sole IL-1β treatment (**p b 0.01, student's t-test, n = 4–5 ani-
mals/group, 2–3 venules/animal). C) Stimulation of the mouse cremaster muscle with
IL-1β (10 ng/ml) time dependently increased vascular permeability, which was further
enhanced by pretreatment with PtpI IV (2 μM, 4 h) (*p b 0.05, two-tailed t-test between
the respective time points, n= 5 animals/group), as assessed by FITC-dextran extravasa-
tion. Representative images of FITC-dextran (green) extravasation in themouse cremaster
muscle before (0 min) and after IL-1β stimulation and PtpI IV treatment, respectively, are
shown next to the graph. Scale bar: 500 μm. D) Number of extravasated leukocytes under
IL-1β stimulation was enhanced after SHP-2 inhibition (2 μM PtpI IV) compared to sham
treatment (**p b 0.01, student's t-test, n= 3 animals/group, each 6 fields of view). Photos
show representative microscopy images of stained cremaster tissues. Scale bar: 100 μm.
White frames: Magnification of selected areas shown to the right; scale bar: 50 μm.
E) Overexpression of SHP-2 CS enhanced IL-1β-induced (10 ng/ml) ICAM-1 and VCAM-
1 surface expression,whereas SHP-2 EA expression prevented this induction, asmeasured
by flow cytometry (*p b 0.05, 1-way ANOVA, n=6 in duplicates). F) Expression of SHP-2
CS in human EC increased IL-1β-dependent (10 ng/ml, 4 h) human leukocyte adhesion
under flow (1 dyn/cm2), whereas SHP-2 EA expression impaired adhesion compared to
SHP-2WT expressing cells (*p b 0.05, 1-way ANOVA, n= 3 each 4–5 visual fields). Repre-
sentative images of human PMN adhesion to human EC expressing SHP-2 mutants are



































































SHP-2 WT CS EA WT CS EA
30´ IL-1βnon stim.


















































































































































































Fig. 4. SHP-2 activity controls IL-1β-induced NF-κB activation. A) IL-1β-dependent (10 ng/ml, 30min) nuclear translocation of the NF-κB subunit p65 in SHP-2mutant ECwas assessed by
immunofluorescence staining (red: p65, blue: DAPI). B) SHP-2 EA expressing cells showed less p65 nuclear translocation upon IL-1β stimulation (*p b 0.05, 1-way ANOVA, n = 3 in
duplicates) compared to SHP-2 WT cells. Graph shows quantification of NF-κB-positive nuclei. C) As no enhancement of p65 nuclear translocation was detected with SHP-2 CS,
potentially due to already maximal response in SHP-2 WT expressing cells, p65 DNA-binding activity was measured. IL-1β induced p65 DNA binding activity in nuclear extracts of
SHP-2 WT expressing EC, which was further enhanced by SHP-2 CS expression (*p b 0.05, 1-way ANOVA, n = 3). D) NF-κB inhibition (Ro 106–9920, 10 μM) prevented enhancement
of IL-1β-dependent ICAM-1 and VCAM-1 upregulation in SHP-2 CS expressing cells (*p b 0.05, 1-way ANOVA, n = 6 in duplicates), as measured by flow cytometry (graph) and
subsequent western blot of the same samples (lower panels). E and F) IL-1β-induced activation of downstream signalling molecules was analyzed by western blot. SHP-2 CS
expression enhanced IL-1β-dependent Akt (n = 12), p38 MAPK (n = 4) and Hsp27 phosphorylation (n = 11) in EC compared to SHP-2 WT (*p b 0.05, 1-way ANOVA). Graphs show
quantitative analysis of protein band intensities.
127Y. Heun et al. / EBioMedicine 42 (2019) 120–132compared to SHP-2WT expression. In contrast, SHP-2 EA impaired this,
as assessed by immunofluorescence staining of nuclear translocation of
the NF-κB subunit p65 (Fig. 4A, B), p65 DNA-binding activity (Fig. 4C),
and phosphorylation of IKK and IκBα (Fig. S4B). Finally, NF-κB inhibi-
tion in SHP-2 CS cells prevented the observed enhancement of ICAM-1
and VCAM-1 surface expression and protein levels in these cells
(Fig. 4D).
Secondly, to identify further signalling molecules upstream of
NF-κB transcriptional activation, pharmacological inhibition ofPI3K, Akt, ERK, and p38 MAPK prior to IL-1β stimulation was per-
formed. Only p38 MAPK inhibition impaired IL-1β-induced ICAM-
1 surface expression and protein levels (Fig. S4C). VCAM-1 expres-
sion was reduced after inhibition of p38 MAPK, PI3K, and Akt
(Fig. S4D). Furthermore, Akt was activated by p38 MAPK and
PI3K (Fig. S4E). Heat shock protein 27 (Hsp27), however, was
only activated by p38 (Fig. S4F), indicating a splitting of the p38-
mediated signalling cascade. Moreover, expression of SHP-2 CS in
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129Y. Heun et al. / EBioMedicine 42 (2019) 120–132MAPK and Akt (Fig. 4E) as well as Hsp27 compared to SHP-2
WT (Fig. 4F).
Lastly, we investigated potential direct targets of SHP-2 through
which the inflammatory response during sepsis may be influenced.
The IL-1R1 adaptor protein MyD88 contains a SH-2 binding motif
(YKAM between amino acids 257–260) shown to influence MyD88
downstream signalling [12]. As MyD88 was IL-1β-dependently
phosphorylated on tyrosine 257 (Fig. S5), we explored if SHP-2 in-
teracts with MyD88. As detected by a proximity ligation assay,
SHP-2 was found to interact with MyD88 upon IL-1β stimulation
(Fig. 5A). Importantly, mutation of the tyrosine 257 in the SH-2 bind-
ing motif of MyD88 (YF) abrogated the IL-1β-mediated interaction
with endogenous SHP-2 (Fig. 5B). SHP-2/MyD88-interaction was
also studied in EC expressingmyc-tagged SHP-2 (WT, CS and EA). In-
terestingly, the previously observed IL-1β-induced interaction be-
tween SHP-2 and MyD88 (Fig. 5A) was even more pronounced
between MyD88 and the inactive mutant construct SHP-2 CS,
confirming its substrate trapping characteristic [42] (Fig. 5C). In con-
trast, SHP-2 EA exhibited a reduced interaction withMyD88, indicat-
ing a quick release of SHP-2 from its target upon dephoshorylation
(Fig. 5C). We furthermore analyzed recruitment of the regulatory
subunit p85 of PI3K to MyD88. Indeed, IL-1β stimulation resulted
in association between MyD88 and the p85 subunit of PI3-K
(Fig. 5D). Although the inactive SHP-2 CS was shown to be trapped
at phospho-Y257 of MyD88 upon IL-1β stimulation, p85 recruitment
to MyD88 was not impaired but even enhanced in these cells com-
pared to SHP-2 WT (Fig. 5E). In contrast, the IL-1β-induced interac-
tion between MyD88 and p85 was prevented in cells expressing
constitutively active SHP-2 EA (Fig. 5E). These data indicate that
SHP-2 binds to phospho-Y257 on MyD88 and may dephosphorylate
a further binding site for p85. An illustration summarizing our find-
ings regarding the regulatory role of SHP-2 in sepsis is shown
in Fig. 6.
4. Discussion
In this study we unveil a novel and important regulatory role of
the tyrosine phosphatase SHP-2 in protecting the endothelium
from inflammation-induced activation. Of note, we found SHP-2
activity in the endothelium to be repressed by ROS during sepsis,
which may constitute a critical step in the disease progression.
In mice suffering from polymicrobial sepsis, exhibiting strongly en-
hanced endothelial adhesionmolecule expression,we detected a persis-
tent suppression of SHP-2 activity. This corresponds to our findings in
blood cells from sepsis patients, where SHP-2 phosphatase activity
was found to be significantly reduced. A similar reduction of SHP-2 ac-
tivity with a directly linked increase in adhesion molecule expression
was observed in primary human endothelial cells (EC) exposed to
serum from sepsis patients, supporting the relevance of SHP-2 activity
in the control of inflammatory endothelial activation. The finding that
inhibition of IL-1 receptor-mediated signallingwas sufficient to reinstall
SHP-2 activity in sepsis serum treated cells suggests that IL-1β is mainly
responsible for SHP-2 inactivation in this condition. This is supported by
the finding that IL-1α, which is also released in sepsis [41] and signals
through the IL-1R [10], did not reduce SHP-2 activity in EC. The mecha-
nism behind this selective inhibition needs to be further investigated.
However, even if IL-1α does not seem to affect SHP-2 activity in EC itFig. 5. SHP-2 interacts with the SH-2 binding motif of MyD88. A) IL-1β stimulation (10 ng/ml, 2
4–5 fields of view), as measured by a proximity ligation assay (PLA). B) HA-taggedMyD88WT
(mutation of Y257 in the SH-2 bindingmotif) did not associate with SHP-2 (*p b 0.05, 1-way AN
interaction between MyD88 and SHP-2 WT upon IL-1β. This interaction was increased betwe
ANOVA, n = 6 each 4–5 fields of view). D) IL-1β stimulation induced interaction between M
view). E) IL-1β-mediated MyD88/p85 interaction was enhanced in EC expressing the substrat
of MyD88 and p85 was prevented in cells expressing SHP-2 EA (*p N 0.05, 1-way ANOVA, n =
right of the respective graph. Specific interaction spots are shown in the left panel. Merge im
phalloidin AF488 (green). Scale bar: 20 μm.is still possible that SHP-2 inactivation by IL-1β influences IL-1α medi-
ated signalling, as they exploit the same signalling molecules, such as
MyD88 and p38MAPK. Whether SHP-2 is involved in the regulation of
the cellular responsesmediated by other pro-inflammatory factors dur-
ing inflammation largely remains to be elucidated. Only a limited num-
ber of studies have investigated the role of SHP-2 in signallingmediated
by other receptors involved in inflammatory responses in sepsis. For
instance, Xu et al. showed that SHP-2 suppresses TLR dependent signal-
ling in macrophages by negatively regulating TRAF-6 [43] and a study
fromAn et al. demonstrated a negative regulation of TLR-3 and -4medi-
ated signalling by SHP-2 at the level of TRIF [44].
The protective role of SHP-2 in inflammatory endothelial activation
is fostered by the prevention of sepsis serum- or IL-1β-induced expres-
sion of endothelial adhesion molecules and leukocyte adhesion by
introduction of a constitutively active SHP-2 mutant. In contrast, ex-
pression of an inactive SHP-2mutant, mimicking the SHP-2 inactivation
in sepsis, worsened the inflammatory phenotype of EC and enhanced
leukocyte adhesion. This illustrates that changes in SHP-2 activity in
sepsis are functionally relevant. Accordingly, pharmacological inactiva-
tion of SHP-2 in mouse microvessels in vivo resulted in significantly en-
hanced leukocyte adhesion, transmigration and vascular permeability
upon IL-1β stimulation. Our data are in line with the work of Coulombe
et al., which found increased leukocyte infiltration into the colon in an
ulcerative colitis model using mice with an SHP-2 deletion in intestinal
epithelial cells [45]. The SHP-2 activity state may therefore determine
the extent of vascular inflammation seen in sepsis and other systemic
inflammatory diseases.
In the course of inflammation, both paracrine as well as local auto-
crine effects of IL-1βmay come into play [46]. The observed continuous
increase in IL-1β serum levels in septic mice may thus be due to in-
creased secretion of IL-1β from recruited inflammatory cells or an auto-
crine positive feedback mechanism, as EC has been demonstrated to
produce and release IL-1β and IL-1β can induce its own expression
[46,47]. Although not investigated here, it may even be possible that
SHP-2 inhibition leads to more IL-1β production in EC, as we showed
that SHP-2 affects NF-κB activity, which is involved not only in the ex-
pression of adhesion molecules but also in the expression of inflamma-
tory cytokines [48]. Thus, the consequences of SHP-2 inactivation
during inflammationmay bemanifold andmay be enhanced by positive
feedback loops.
SHP-2 is known to associate with a multitude of receptors and
their adaptor molecules and in this way regulates their downstream
signalling [49,50]. MyD88 is an adaptor protein binding to the IL-1R,
IL-18R and several Toll-like receptors (TLRs) [51,52]. Our findings
that SHP-2 inhibition enhanced IL-1β-induced adhesion molecule
expression and vascular leakage, both processes shown to depend
on MyD88 [6], tempted us to investigate a possible link between
SHP-2 phosphatase activity and MyD88. SHP-2 binds via its SH2-
domains to phosphorylated tyrosines on target molecules [53]. As
MyD88 was shown by us and others to become tyrosine phosphory-
lated [54,55], we hypothesized that SHP-2 may be recruited to this
adaptor protein upon IL-1β stimulation. In fact, we found that SHP-
2 interacts directly with the SH2-domain binding motif (YKAM) of
MyD88 upon IL-1β stimulation, as the MyD88 Y257F mutant, lacking
this binding motif, failed to bind SHP-2. It has been postulated that
this motif is crucial for p85/PI3K recruitment to MyD88 and corre-
sponding downstream signalling [12,55,56], which would implymin) of EC induced MyD88 association with SHP-2 (*p b 0.05, student's t-test, n = 6 each
interactedwith endogenous SHP-2 upon IL-1β stimulation, whereas HA-taggedMyD88 YF
OVA, n= 7 each 4 fields of view). C) PLA withmyc-tagged SHP-2WT, CS and EA revealed
en SHP-2 CS and MyD88, but impaired between SHP-2 EA and MyD88 (p b 0.05, 1-way
yD88 and the p85 subunit of the PI3-K (*p b 0.05, student's t-test, n = 6 each 4 fields of
e trapping and inactive mutant SHP-2 CS compared to SHP-2 WT. In contrast, interaction
6 each 4 fields of view). Representative images of all PLA experiments are shown to the
ages (right): PLA spots (red), nuclear staining with DAPI (blue) and actin staining with
130 Y. Heun et al. / EBioMedicine 42 (2019) 120–132competitive binding of SHP-2 and p85. However, we did not find ev-
idence for a competitive binding of these molecules at this site. Both
SHP-2 and p85 showed an increased association to MyD88 to a sim-
ilar extent upon IL-1β stimulation, indicating that they are using dif-
ferent binding sites. This conclusion is supported by the observation
that occupation of the Y257 within the YKAMmotif of MyD88 by the
substrate trapping mutant SHP-2 CS did not hamper p85 binding to
MyD88 but even enhanced p85/MyD88 interaction. Therefore,
based on these findings we propose an alternative model in which
SHP-2 binds to the phosphorylated tyrosine in the SH-2 binding
motif of MyD88 upon IL-1β stimulation, probably enabling the de-
phosphorylation of a different p85 binding site and subsequent inhi-
bition of downstream signalling. This model is further highlighted by
our finding that the interaction between MyD88 and p85 was re-
duced in cells expressing the constitutively active SHP-2 EA. Our
model is in accordance with the study of Laird et al. [57], which
showed that p85 binding to MyD88 occurs even if the SH-2 binding
motif is mutated. In fact, screening of the PhosphoSitePlus® data-
base revealed that MyD88 features two more tyrosine residues
(Y187 and Y276) within its Toll/interleukin-1 receptor (TIR) do-
main, the functions of which remain to be studied, however. This
mechanism may represent a vascular protective axis, limiting endo-
thelial inflammatory responses and thus preventing vascular injury
(see Fig. 6 for a summary). The high basal activity of SHP-2 is a fur-
ther indication of its importance in maintaining endothelial
quiescence.Fig. 6. Proposed model for the role of SHP-2 in the regulation of IL-1β-dependent EC signalling
under physiological conditions. Thus, SHP-2 may preserve endothelial quiescence by keep
inflammatory downstream signalling via interaction partners of MyD88 such as PI3-K. B) Upo
of SHP-2. However, inflammation-induced generation of ROS results in inactivation of SHP-2
protective effect of SHP-2. Hence, a different SH-2 binding site is phosphorylated, resultin
downstream signalling including p38 MAPK, AKT, Hsp27 and NF-κB. Consequently, express
recruitment as well as enhanced vascular leakage (not shown). The reactivation of SHP-2 acti
extensive inflammatory responses mediated by MyD88 during inflammatory diseases such asMost interestingly, the suppressed SHP-2 activity in EC upon expo-
sure to IL-1β and sepsis serum could be completely prevented by inhi-
bition of ROS production. Indeed, ROS is a well-known mediator of
endothelial inflammation [58], and SHP-2 activity has been shown to
be inhibited by ROS-dependent oxidation of the critical cysteine residue
in the catalytic pocket of SHP-2 [59,60]. Of note, sepsis patients were
found to exhibit an impaired SHP-2 activity. In addition, the observation
that IL-1βwas enhanced in serum from septicmice for at least 48 hmay
explain the persistent SHP-2 inhibition observed in these animals. How-
ever, we cannot exclude a possible disinhibition of NAD(P)H-oxidase
upon SHP-2 inactivation, which may additionally contribute to the
long-term inactivation of SHP-2 in EC. On the basis of our data we
thus propose that an inactivation of SHP-2 caused by cytokine-
induced excessive ROS production is a crucial event in the induction of
the endothelial adhesive phenotype in sepsis. This notion is further en-
dorsed by the finding that restoration of SHP-2 activity by introduction
of constitutively active SHP-2 prevented the inflammatory phenotype.
This strengthens our initial belief that SHP-2 has a protective effect in
the endothelium and most importantly demonstrates that SHP-2 activ-
ity can be restored during inflammatory conditions and thusmay repre-
sent a putative future therapeutic target in sepsis. In inflammatory
states, such as sepsis, we thus suggest that SHP-2 interacts with
MyD88 upon phosphorylation of tyrosine 257. However, excessive
ROS formation inhibits the phosphatase activity of SHP-2 and prevents
it from dephosphorylating other phosphorylation sites on MyD88 im-
portant for binding of signalling molecules, such as the p85 subunit ofand vascular inflammation. A) The tyrosine phosphatase SHP-2 possesses a basal activity
ing MyD88 phospho-tyrosine sites in a dephosphorylated state, thereby limiting pro-
n activation of the IL-1R1 by IL-1β, MyD88 is phosphorylated on Y257 enabling binding
by oxidation of the critical cysteine residue in the phosphatase domain suspending the
g in recruitment of p85/PI3-K to MyD88 and subsequent activation of inflammatory
ion of ICAM-1 and VCAM-1 at the endothelial surface is induced followed by leukocyte
vity by IL-1Ra or ROS inhibition may be a promising therapeutic approach to prevent the
sepsis.
131Y. Heun et al. / EBioMedicine 42 (2019) 120–132the PI3-K, resulting in activation of signalling pathways, such as p38
MAPK, Akt, Hsp27, and NF-κB, and thus endothelial activation. Thera-
peutic application of ROS-inhibitors in the context of sepsis may rein-
stall endothelial SHP-2 activity and accordingly improve endothelial
physiology. If this holds true in a clinical setting, needs further
investigation.
In summary, our data provide novel evidence that SHP-2 is critical in
the regulation of IL-1β-induced vascular dysfunction. While it physio-
logically downregulates IL-1β-dependent signalling, thereby limiting
adhesion molecule expression, leukocyte adhesion and transmigration
in vitro and in vivo, its inactivation results in inflammatory over-
activation of the endothelium. Interaction of SHP-2 and MyD88 at tyro-
sine 257 in the SH-2 binding motif of MyD88 controls inflammatory
downstream signalling and cellular responses. Of particular importance,
repression of SHP-2 activity via ROS in sepsis therefore accelerates the
endothelial inflammatory response. Physiological integrity of SHP-2 ac-
tivity is therefore essential to prevent an inflammatory state of the en-
dothelium, as in sepsis, and maintaining SHP-2 activity may be a
therapeutic target to prevent endothelial dysfunction and capillary
leakage.
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